S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)

Cardiff Oncology Stock Price, News & Analysis (NASDAQ:CRDF)

$1.26
+0.03 (+2.44%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.21
$1.26
50-Day Range
$0.96
$1.62
52-Week Range
$0.94
$2.79
Volume
97,046 shs
Average Volume
447,478 shs
Market Capitalization
$56.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Cardiff Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
931.7% Upside
$13.00 Price Target
Short Interest
Healthy
3.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Cardiff Oncology in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.99) to ($1.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

574th out of 949 stocks

Biological Products, Except Diagnostic Industry

94th out of 160 stocks


CRDF stock logo

About Cardiff Oncology Stock (NASDAQ:CRDF)

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CRDF Stock Price History

CRDF Stock News Headlines

Cardiff Oncology Inc CRDF
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Piper Sandler Sticks to Its Buy Rating for Cardiff Oncology (CRDF)
Why Cardiff Oncology Stock Is Rising After Hours
Cardiff Oncology soars as Pfizer backs lead program
See More Headlines
Receive CRDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/07/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRDF
Fax
N/A
Employees
25
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$13.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+956.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-38,700,000.00
Net Margins
-8,875.00%
Pretax Margin
-8,869.78%

Debt

Sales & Book Value

Annual Sales
$390,000.00
Book Value
$1.74 per share

Miscellaneous

Free Float
41,862,000
Market Cap
$54.96 million
Optionable
Not Optionable
Beta
1.77

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Mark Erlander Ph.D. (Age 63)
    CEO & Director
    Comp: $2.43M
  • Mr. James E. LevineMr. James E. Levine (Age 52)
    Chief Financial Officer
    Comp: $1.57M
  • Dr. Tod Smeal Ph.D. (Age 58)
    Chief Scientific Officer?
    Comp: $2.69M
  • Ms. Elizabeth Anderson
    VP of Finance & Administration
  • Ms. Brigitte Lindsay
    Senior Vice President of Finance
  • Mr. Charles Monahan R.Ph.
    Senior VP of Regulatory Affairs
  • Dr. Fairooz Kabbinavar FACP (Age 65)
    M.D., Chief Medical Officer














CRDF Stock Analysis - Frequently Asked Questions

Should I buy or sell Cardiff Oncology stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CRDF shares.
View CRDF analyst ratings
or view top-rated stocks.

What is Cardiff Oncology's stock price target for 2024?

1 Wall Street research analysts have issued 1-year target prices for Cardiff Oncology's stock. Their CRDF share price targets range from $13.00 to $13.00. On average, they expect the company's stock price to reach $13.00 in the next year. This suggests a possible upside of 931.7% from the stock's current price.
View analysts price targets for CRDF
or view top-rated stocks among Wall Street analysts.

How have CRDF shares performed in 2023?

Cardiff Oncology's stock was trading at $1.40 on January 1st, 2023. Since then, CRDF stock has decreased by 10.0% and is now trading at $1.26.
View the best growth stocks for 2023 here
.

When is Cardiff Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our CRDF earnings forecast
.

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:CRDF) posted its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.07. The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.08 million. Cardiff Oncology had a negative net margin of 8,875.00% and a negative trailing twelve-month return on equity of 44.47%.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA).

Who are Cardiff Oncology's major shareholders?

Cardiff Oncology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.19%), Jacobs Levy Equity Management Inc. (0.15%), Callan Capital LLC (0.07%), GSA Capital Partners LLP (0.06%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Gary W Pace, James E Levine, John P Brancaccio, Lale White, Mark Erlander, Renee P Tannenbaum, Rodney S Markin and Vicki Kelemen.
View institutional ownership trends
.

How do I buy shares of Cardiff Oncology?

Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CRDF) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -